Cardio-oncology & otherCohort study
Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment
- Matched cohort study
- population-based
- Danish registries
- matched (birth year, sex, calendar year)
Authors' conclusion
Several cardiovascular disease risks were elevated among cancer survivors, with substantial variation by cancer type and treatment.
Study context
- Population
- Cancer survivors previously treated with systemic cancer therapy, Danish population-based registries
- Participants
- 91,407 vs 457,035
- Exposure
- Cancer survivors vs Matched individuals
- Cancer survivorsn = 91,407
- Matched individualsn = 457,035reference
- Outcome
- Risk of CVD
- Follow-up
- Up to 5 years from index date (3 years after diagnosis)
Main finding
As reported in the abstract
Cancer survivors vs Matched individualsHazard ratio (95% CI)
HF or cardiomyopathy
1.08(1.02–1.15)
VTE
1.50(1.41–1.61)
pericarditis, endocarditis or myocarditis
1.30(1.11–1.52)
kidney failure
1.17(1.10–1.25)
Observational data: associations, not effects.
Further findings
CVD risks by cancer type and treatment agent (subgroups)
- Estimates varied substantially by cancer type and treatment agent
- VTE risk increased across nearly all cancer types; hypertension risk elevated for none
- Ischemic heart disease risk increased only among lung cancer survivors
- Stroke associated with platinum compounds but not other systemic treatments
Original publication
Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment. JACC CardioOncol. doi:10.1016/j.jaccao.2025.03.008
Summarised from the published abstract; every number is checked against it